Shane Barton's most recent trade in BioAge Labs Inc. was a trade of 42,350 Common Stock done at an average price of $25.2 . Disclosure was reported to the exchange on June 29, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| BioAge Labs Inc | Shane Barton | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 25.21 per share. | 29 Jun 2026 | 42,350 | 0 | - | 25.2 | 1,067,576 | Common Stock |
| BioAge Labs Inc | Shane Barton | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 25.19 per share. | 29 Jun 2026 | 20,216 | 0 | - | 25.2 | 509,176 | Common Stock |
| BioAge Labs Inc | Shane Barton | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jun 2026 | 14,198 | 75,802 | - | - | Stock Option (Right to Buy) | |
| BioAge Labs Inc | Shane Barton | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.38 per share. | 29 Jun 2026 | 14,198 | 42,350 | - | 4.4 | 62,187 | Common Stock |
| BioAge Labs Inc | Shane Barton | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.85 per share. | 29 Jun 2026 | 9,301 | 11,933 | - | 10.9 | 100,916 | Common Stock |
| BioAge Labs Inc | Shane Barton | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jun 2026 | 9,301 | 17,589 | - | - | Stock Option (Right to Buy) | |
| BioAge Labs Inc | Shane Barton | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jun 2026 | 8,958 | 31,042 | - | - | Stock Option (Right to Buy) | |
| BioAge Labs Inc | Shane Barton | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.30 per share. | 29 Jun 2026 | 8,958 | 28,152 | - | 4.3 | 38,519 | Common Stock |
| BioAge Labs Inc | Shane Barton | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jun 2026 | 7,861 | 67,941 | - | - | Stock Option (Right to Buy) | |
| BioAge Labs Inc | Shane Barton | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.38 per share. | 29 Jun 2026 | 7,861 | 20,216 | - | 4.4 | 34,431 | Common Stock |
| BioAge Labs Inc | Shane Barton | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jun 2026 | 7,261 | 21,016 | - | - | Stock Option (Right to Buy) | |
| BioAge Labs Inc | Shane Barton | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.39 per share. | 29 Jun 2026 | 7,261 | 19,194 | - | 8.4 | 60,920 | Common Stock |
| BioAge Labs Inc | Shane Barton | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jun 2026 | 4,290 | 13,299 | - | - | Stock Option (Right to Buy) | |
| BioAge Labs Inc | Shane Barton | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.85 per share. | 29 Jun 2026 | 4,290 | 4,290 | - | 10.9 | 46,547 | Common Stock |
| BioAge Labs Inc | Shane Barton | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jun 2026 | 4,065 | 26,977 | - | - | Stock Option (Right to Buy) | |
| BioAge Labs Inc | Shane Barton | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.30 per share. | 29 Jun 2026 | 4,065 | 12,355 | - | 4.3 | 17,480 | Common Stock |
| BioAge Labs Inc | Shane Barton | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jun 2026 | 4,000 | 17,016 | - | - | Stock Option (Right to Buy) | |
| BioAge Labs Inc | Shane Barton | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.39 per share. | 29 Jun 2026 | 4,000 | 8,290 | - | 8.4 | 33,560 | Common Stock |
| BioAge Labs Inc | Shane Barton | Principal Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2026 | 45,000 | 45,000 | - | - | Stock Option (Right to Buy) | |
| BioAge Labs Inc | Shane Barton | Principal Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2025 | 90,000 | 90,000 | - | - | Stock Option (Right to Buy) | |
| Precision Biosciences Inc | Shane Barton | VP & Corporate Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jun 2023 | 6,060 | 27,502 (0%) | 0% | - | Common Stock | |
| Precision Biosciences Inc | Shane Barton | VP & Corporate Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jun 2023 | 6,060 | 6,060 | - | - | Restricted Stock Units | |
| Precision Biosciences Inc | Shane Barton | VP & Corporate Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2023 | 12,722 | 25,439 | - | - | Restricted Stock Units | |
| Precision Biosciences Inc | Shane Barton | VP & Corporate Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2023 | 12,722 | 21,422 (0%) | 0% | - | Common Stock | |
| Precision Biosciences Inc | Shane Barton | VP & Corporate Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jan 2023 | 70,000 | 70,000 | - | - | Restricted Stock Units | |
| Precision Biosciences Inc | Shane Barton | VP & Corporate Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jun 2022 | 6,061 | 8,720 (0%) | 0% | - | Common Stock | |
| Precision Biosciences Inc | Shane Barton | VP & Corporate Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jun 2022 | 6,061 | 12,120 | - | - | Restricted Stock Units |